The Oncogene Metadherin Interacts with the Known Splicing Proteins YTHDC1, Sam68 and T-STAR and Plays a Novel Role in Alternative mRNA Splicing.
CD44
SAM68
YTHDC1
alternative splicing
prostate cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Aug 2019
23 Aug 2019
Historique:
received:
17
07
2019
revised:
13
08
2019
accepted:
21
08
2019
entrez:
28
8
2019
pubmed:
28
8
2019
medline:
28
8
2019
Statut:
epublish
Résumé
Oncogenic metadherin is a key contributor to tumourigenesis with metadherin expression and cytoplasmic localisation previously linked to poor survival. A number of reports have shown metadherin localises specifically to nuclear speckles known to be rich in RNA-binding proteins including the splicing proteins YTHDC1, Sam68 and T-STAR, that have been shown to select alternative splice sites in mRNA of tumour-associated proteins including BRCA, MDM2 and VEGF. Here we investigate the interaction and relationship between metadherin and the splice factors YTHDC1, T-STAR and Sam68. Using a yeast two-hybrid assay and immunoprecipitation we show that metadherin interacts with YTHDC1, Sam68 and T-STAR and demonstrate that T-STAR is significantly overexpressed in prostate cancer tissue compared to benign prostate tissue. We also demonstrate that metadherin influences splice site selection in a dose-dependent manner in CD44v5-luc minigene reporter assays. Finally, we demonstrate that prostate cancer patients with higher metadherin expression have greater expression of the CD44v5 exon. CD44v5 expression could be used to discriminate patients with poor outcomes following radical prostatectomy. In this work we show for the first time that metadherin interacts with, and modulates, the function of key components of splicing associated with cancer development and progression.
Identifiants
pubmed: 31450747
pii: cancers11091233
doi: 10.3390/cancers11091233
pmc: PMC6770463
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Medical Research Council
ID : MR/S005897/1
Pays : United Kingdom
Organisme : Prostate Cancer UK
ID : PG14-014
Pays : United Kingdom
Organisme : Prostate Cancer UK
ID : TLD-PF16-004
Pays : United Kingdom
Organisme : Rosetrees Trust
ID : A1383 UCL
Références
Exp Cell Res. 2004 Oct 15;300(1):134-48
pubmed: 15383321
J Cell Biol. 2013 Oct 14;203(1):149-64
pubmed: 24127217
Endocr Relat Cancer. 2011 Jul 01;18(4):R91-R102
pubmed: 21565971
Exp Cell Res. 2004 Mar 10;294(1):94-105
pubmed: 14980505
EMBO J. 2001 Aug 1;20(15):4194-203
pubmed: 11483522
Mol Cell. 2012 Apr 27;46(2):187-99
pubmed: 22424772
Cancer Res. 2006 Feb 1;66(3):1509-16
pubmed: 16452207
Hum Mol Genet. 2004 Aug 1;13(15):1535-49
pubmed: 15175272
Oncogene. 2007 Dec 6;26(55):7647-55
pubmed: 17563745
FEBS Lett. 1997 Jun 9;409(2):237-41
pubmed: 9202153
Biochem Soc Trans. 2008 Jun;36(Pt 3):505-7
pubmed: 18481990
Cancer Cell. 2011 Dec 13;20(6):768-80
pubmed: 22172722
J Cell Biochem. 2012 Jul;113(7):2319-29
pubmed: 22345078
Int J Biochem Cell Biol. 2017 Oct;91(Pt B):168-175
pubmed: 28743674
Trends Biochem Sci. 2002 Oct;27(10):495-7
pubmed: 12368078
Nature. 2002 Dec 12;420(6916):691-5
pubmed: 12478298
Oncotarget. 2016 Aug 16;7(33):53362-53376
pubmed: 27438142
Front Oncol. 2019 May 03;9:349
pubmed: 31131259
Prostate. 2007 Jun 15;67(9):943-54
pubmed: 17440980
J Hematol Oncol. 2018 May 10;11(1):64
pubmed: 29747682
Oncogene. 2008 Jan 17;27(4):548-56
pubmed: 17621265
Biomolecules. 2019 Apr 01;9(4):
pubmed: 30939845
RNA. 2018 May;24(5):688-703
pubmed: 29438049
Genes (Basel). 2017 Dec 29;9(1):null
pubmed: 29286307
J Cell Biol. 2010 Oct 4;191(1):87-99
pubmed: 20876280
Biochem Soc Trans. 2016 Aug 15;44(4):1066-72
pubmed: 27528753
Curr Opin Struct Biol. 2017 Jun;44:18-30
pubmed: 27838525
Biochem Biophys Res Commun. 2008 Jun 27;371(2):333-8
pubmed: 18440304
J Cell Biol. 2000 Sep 4;150(5):949-62
pubmed: 10973987
Diagn Pathol. 2014 Nov 29;9:221
pubmed: 25432701
Tumour Biol. 2015 Aug 21;:null
pubmed: 26289848
J Struct Biol. 2000 Apr;129(2-3):233-40
pubmed: 10806073
Nucleic Acids Res. 1990 Sep 11;18(17):5322
pubmed: 1698283
Mol Carcinog. 2014 Nov;53(11):883-92
pubmed: 23765422
PLoS One. 2013 Jul 29;8(7):e70596
pubmed: 23923007
Cancer Res. 2001 Feb 15;61(4):1375-81
pubmed: 11245437
Adv Cancer Res. 2016;131:97-132
pubmed: 27451125
Oncogene. 2009 Oct 15;28(41):3663-70
pubmed: 19648967
Prostate. 2018 Dec;78(16):1229-1237
pubmed: 30073682
Mol Biol Cell. 1999 Nov;10(11):3909-26
pubmed: 10564280
Theranostics. 2018 Feb 12;8(7):1752-1765
pubmed: 29556354
RNA Biol. 2012 Sep;9(9):1129-33
pubmed: 23018781
Clin Cancer Res. 2009 May 1;15(9):3003-13
pubmed: 19383828
Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1238-60
pubmed: 26921821
Oncogene. 2009 Sep 10;28(36):3188-96
pubmed: 19633686
Nucleic Acids Res. 2010 May;38(9):3005-18
pubmed: 20110258
Int J Gynecol Cancer. 2010 May;20(4):492-9
pubmed: 20686370
J Pathol. 2008 May;215(1):67-77
pubmed: 18273831
BMC Urol. 2015 Sep 04;15:91
pubmed: 26334874
Mol Biol Cell. 1999 Sep;10(9):3015-33
pubmed: 10473643